Desafiando a la inequidad de Latinoamérica: estrategias facilitadoras de “control” de la Enfermedad Renal Crónica
| dc.contributor.author | Depine, Santos Ángel | |
| dc.contributor.author | Aroca Martínez, Gustavo | |
| dc.date.accessioned | 2018-09-12T17:19:24Z | |
| dc.date.available | 2018-09-12T17:19:24Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Este libro nace del análisis de las situaciones de desigualdad e inequidad en la que se encuentran los países de la región Latinoamericana y el Caribe, incluso con núcleos de población al interior de los mismos en situaciones de mayor vulnerabilidad. Los autores realizaron una exhaustiva revisión y análisis de las evidencias disponibles, para diseñar nuevas estrategias de accesibilidad a los medicamentos, insumos, equipamiento y reactivos de laboratorio necesarios para facilitar el tratamiento y control adecuado de los pacientes con enfermedades renales, incluyendo a la enfermedad renal crónica (ERC). Los resultados obtenidos permitieron concretar y proponer una lista detallada y justificada de equipamiento, insumos y reactivos de laboratorio, utilizados en todos los estadios de enfermedad renal, factibles de ser incluidos en estrategias de compra mayoristas supranacionales, con el objeto de abaratar su costo, o en estrategias nacionales de suministro subsidiado, mejorando la accesibilidad, el tratamiento y la calidad de vida de las poblaciones más vulnerables. | spa |
| dc.identifier.isbn | 9789585430723 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/2283 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.rights.license | Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | spa |
| dc.subject | Nefrología | spa |
| dc.subject | Riñones | spa |
| dc.subject | Insuficiencia Renal Crónica | spa |
| dc.subject | Enfermedades crónicas | spa |
| dc.title | Desafiando a la inequidad de Latinoamérica: estrategias facilitadoras de “control” de la Enfermedad Renal Crónica | spa |
| dc.type | Book | spa |
| dcterms.references | AAMI (2007). Water Treatment Equipment for Hemodialysis Applications (ANSI/AAMI RD62:2006). American National Standard. Arlington (VA): AAMI, 2006. Arlington: Association for the Advancement of Medical Instrumentation. | eng |
| dcterms.references | ADA (2011). Standards of Medical Care in Diabetes, 2011. Diabetes Care, 34 (Supplement 1), S11-S61. | eng |
| dcterms.references | Aroca-Martínez, G. A. (2017). Propuesta de un modelo de gestión de salud de la Nefritis Lúpica, basado en la problemática clínica y su impacto socio-sanitario en la región Caribe colombiana. Barranquilla: Mejoras. | spa |
| dcterms.references | Aroca Martínez, G., Castillo, A., Bonfantt, A., Torres, H. G., Galindo, H. & Depine, S. (2015). Glomerulonefritis primarias en niños que asisten a un Centro de Referencia en la región Caribe colombiana. Rev. Colomb. Nefrol., 2(1), 12-18. | spa |
| dcterms.references | Baber, U., Toto, R. & Lemos, J. D. (2007). Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J., 153(4), 471-477. | eng |
| dcterms.references | Baigent, C., Landray, M., Reith, C., Emberson, J., Wheeler, D. & Tomson, C., . . . et al. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled. Lancet, 377(9784), 2181-2192. | eng |
| dcterms.references | Baker, L., Muir, J., Sharman, V., Abrams, S., Greenwood, R., Cattell, W., . . . et al. (1986). Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol., 26(4), 185-191. | eng |
| dcterms.references | Barnett, A., Bain, S., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J. & Mustonen, J. (2004). Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Engl J Med., 351(19), 1952-1961. | eng |
| dcterms.references | Barreto, D., Barreto, F. C., Carvalho, A. D., Cuppari, L., Draibe, S., Dalboni, M., . . . Canziani, M. (2008). Phosphate binder impact on bone remodeling and coronary calcification, results from the BRiC study. Nephron Clin Pract., 110(4), 273-283. | eng |
| dcterms.references | Barril, G., González-Parra, E., Alcazar, R., Arenas, M., Campistol, J., Caramelo, C., . . . Teruel, J. (2004). Guías sobre enfermedades víricas en hemodiálisis. Nefrología, 24(Suppl. 2), 43-66. | spa |
| dcterms.references | Bello, A., Peters, J., Rigby, J., Rahman, A., . . . et al. (2008). Socioeconomic status and chronic kidney disease at presentation to a renal service in the United Kingdom. Clin J Am Soc Nephrol., 3(5), 1316-1323. | eng |
| dcterms.references | Block, G., Spiegel, D., Ehrlich, J., Mehta, R., Lindbergh, J., Dreisbach, A. & Raggi, P. (2005). Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int., 68(4), 1815-1824. | eng |
| dcterms.references | Bover, J. & Cozzolino, M. (2011). Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. Kidney Inter. Suppl., 1(4), 122-129. | eng |
| dcterms.references | Brenner, B., Cooper, M., Zeeuw, D. D., Keane, W., Mitch, W., Parving, H., . . . Investigators, R. S. (2001). Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345(12), 861-869. | eng |
| dcterms.references | Brito-Ashurst, I. D., Varagunam, M., Raftery, M. & Yaqoob, M. (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol., 20(9), 2075-2084. | eng |
| dcterms.references | Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., . . . Zitzelsberger, L. (2010). AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ, 182(18), 839-842. | eng |
| dcterms.references | Burgos Calderón, R. & Depine, S. (2005). Sustainable and tenable renal health model: A Latin American proposal of classification, programming, and evaluation. Kidney International, S23–S30. | eng |
| dcterms.references | Burgos Calderón, R. & Depine, S. (2010). Systematic approach for the management of chronic kidney disease: moving beyond chronic kidney disease classification. Curr Opin Nephrol Hypertens, 19(2), 208-13. | eng |
| dcterms.references | Cameron, J. (1999). European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant., 14(Suppl 2), 61-65. | eng |
| dcterms.references | Cannata-Andía, J. B., & Fernández-Martín., J. L. (2002). The clinical impact of aluminium overload in renal failure. Nephrology Dialysis Transplantation, 17 (Suppl. 2)(12), 9-12. | eng |
| dcterms.references | CDC (1988). Centers for Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus (HIV), hepatitis B virus and ther bloodborne pathogens in health-care settings. MMWR, 37(24), 377-388. | eng |
| dcterms.references | CEPAL (2012) Comisión Económica para América Latina y el Caribe, sobre la base de Banco de Datos de Encuestas de Hogares (BADEHOG). | spa |
| dcterms.references | CEPAL (2015) Comisión Económica para América Latina y el Caribe, sobre la base de Banco de Datos de Encuestas de Hogares (BADEHOG). | spa |
| dcterms.references | CEPAL, C. E. (2017). Panorama Social de América Latina 2016. Santiago: Naciones Unidas. | spa |
| dcterms.references | Challú, A., Burgos Calderón, R., Depine, S., Feler, D., & Manzor, D. (1999). La Nefrología en Latinoamérica. Estado Actual. Pautas para su desarrollo. Buenos Aires: SLANH. | spa |
| dcterms.references | Challú, A., Depine, S., San Martín, C., Jost, L. & Estraviz, H. (1990). Realidad de la nefrología latinoamericana. Revista de Nefrología, Diálisis y Transplante, (27), 21-31. | spa |
| dcterms.references | Chamberlain, I., Okonofua, E., Nzerue, M., . . . et al. (1999). Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int., 56(19), 1058-1063. | eng |
| dcterms.references | Chertow, G., Ackert, K., Lew, N., Lazarus, J. & Lowrie, E. (2000). Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int., 58(6), 2512-2517. | eng |
| dcterms.references | Chertow, G., Burke, S. & Raggi, P. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int., 62(1), 245-252. | eng |
| dcterms.references | Clarke, P., Gray, A., Adler, A., . . . et al. (2001). Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS no. 51). Diabetología, 44(3), 298-304. | eng |
| dcterms.references | Coburn, J., Maung, H., Elangovan, L., Germain, M., Lindberg, J., Sprague, S., . . . Bishop, C. (2004). Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis., 43(5), 877-890. | eng |
| dcterms.references | Comos, J. D. (2001). Determinación de aluminio en líquidos concentrados de hemodiálisis por espectrofotometría de absorción atómica: memoria para optar al grado de Doctor. Tesis. Universidad Complutense de Madrid. Facultad de Farmacia, Madrid. | spa |
| dcterms.references | Consortium, A. N. (2009). El Instrumento AGREE II Versión electrónica. Obtenido de AGREE Next Steps Consortium. El Instrumento AGREE II Versión http://www.agreetrust.org | eng |
| dcterms.references | Control, C. F. & CDC. (1988). Update: Universal precautions for prevention of transmission of human immunodeficiency virus (HIV), hepatitis B virus and ther bloodborne pathogens in heath-care settings. MMWR, 37, 377-382; 387-388. | eng |
| dcterms.references | Crews, D., Charles, R. F., Evans, M., Zonderman, A. & Powe, N. (2010). Poverty, Race, and CKD in a Racially and Socioeconomically Diverse Urban Population. Am J Kidney Dis., 55(6), 992-1000. | eng |
| dcterms.references | Depine, S. (1990). Plan de Prevención y Asistencia de la Insuficiencia Renal Crónica (PAIR). Reunión de Acuerdo de Sociedades Latinoamericanas de Nefrología. Rosario. | spa |
| dcterms.references | Depine, S. (1998). Atención gerenciada en nefrología, un desafío de este tiempo. Revista de Nefrología, Diálisis y Transplante (suplemento), 12. | spa |
| dcterms.references | Depine, S. (2009). The role of government and competing priorities in minority populations and developing nations. (K. C. Norris, Ed.). Ethnicity & Disease, 19(S1), 73-9. | eng |
| dcterms.references | Depine, S. & Burgos Calderón, R. (2006). Renal Health Models in Latin America: Development of National Programs of Renal Health. Renal Failure, 28, 649–664. | eng |
| dcterms.references | ERA & Associaton, E. R. (2002). European best practice guidelines for haemodialysis. Section VI. Haemodialysis associated infection. Nephrol Dial Transplant, 17(Suppl 7), 72-87. | eng |
| dcterms.references | FDA & Nutrition, C. F. (s.f.). U.S. Food & Drug Administration. Obtenido de https://www.fda.gov/AboutFDA/CentersOffices/ OfficeofFoods/CFSAN/ | spa |
| dcterms.references | Fellstrom, B. C., Jardine, A., Schmieder, R., Holdaas, H., Bannister, K., J., J. B., et al. (2009). Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med., 360(14), 1395-1407. | eng |
| dcterms.references | Figa, P. A., Compte, M. T., Gallego, C. & Aguilar, C. (2008). Is it necessary to measure anti-hepatitis B antibodies every six months instead of every twelve months in patients on hemodialysis? Nefrología, 28(2), 227-228. | eng |
| dcterms.references | Fondo Monetario Internacional (2017). Perspectivas de la Economía Mundial: ¿Está cobrando impulso? Washington: International Monetary Fund, Publication Services. | spa |
| dcterms.references | Fund, I. M. (2018). World Economic Outlook Database. Recuperado el 21 de mayo de 2018, de http://www.imf.org/en/Publications/ WEO/Issues/2018/03/20/world-economic-outlook-april-2018 | spa |
| dcterms.references | Fundación Mexicana del Riñón, A. C. (2012). Guías Latinoamericanas de Práctica Clínica sobre la Prevención, Diagnóstico y Tratamiento de los Estadios 1-5 de la Enfermedad Renal Crónica (G. T. Vera, Ed.). México: Programas Educativos, S. A. de C. V. | spa |
| dcterms.references | García-García, G. (2014). La pobreza: el denominador común de la amenaza mundial de la ERC. Traducido de MEDICC Review, 16(2), 83. | spa |
| dcterms.references | GBD (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388(10053), 1459-1544. | eng |
| dcterms.references | Go, A. S., Chertow, G., Fan, D., Dongjie F., McCulloch C. E. & Hsu, C. Y. (2004). Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med., 351, 1296-1305. | eng |
| dcterms.references | González-Bedat, M. C., Rosa-Díez, G. & Ferreiro, A. (2017). El Registro Latinoamericano de Diálisis y Trasplante Renal: la importancia del desarrollo de los registros nacionales en Latinoamérica. Nefrol. Latinoam., 14(1), 12-21. | spa |
| dcterms.references | Hemodialysis, E. B., & Association, E. R. (2002). European best practice guidelines for haemodialysis. Section VI. Haemodialysis associated infection. Nephrol Dial Transplant., 17 (Suppl.7), 72-87. | eng |
| dcterms.references | Hoenich, N., Thijssen, S., Kitzler, T., Levin, R., & Ronco, C. (2008). Impact of Water Quality and Dialysis Fluid Composition on Dialysis Practice. Blood Purif., 26(6), 6-11. | eng |
| dcterms.references | Holtkamp, F., Zeeuw, D. D., Thomas, M., Cooper, M., Graeff, P. D., Hillege, H., . . . Heerspink, H. L. (2011). An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int., 80(3), 282-287. | eng |
| dcterms.references | Hou, F., Zhang, X., Zhang, G., Xie, D., Chen, P., Zhang, W., . . . Geng, R. (2006). Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med., 354(2), 131-140. | eng |
| dcterms.references | ISN (2017). ISN serie del Foro Global de Política Pública sobre la enfermedad renal: Enfoque en América Latina. Recuperado el 15 de mayo de 2018, de https://www.theisn.org/images/SPANISH_ Policy_Forum_8_pager_DEF_25092017_interactive.pdf | eng |
| dcterms.references | K/DOQI (2003). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis., 42(4 Suppl 3), S1-201. | eng |
| dcterms.references | K/DOQI (2004). KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis., 43(5 Suppl 1), 1-290. | eng |
| dcterms.references | K/DOQI (2006). K/DOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney diseases. Am J Kidney Dis., 47(Suppl 3), 1-146. | eng |
| dcterms.references | KDIGO (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl., 113, S, 1-130. | eng |
| dcterms.references | KDIGO (2017). Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, 7 Suppl.(1), 1-59. | eng |
| dcterms.references | KDIGO & Group, I. G. (2013). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl., 3, 1-150. | eng |
| dcterms.references | KDIGO, K. D. & Work-Group, C.-M. (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl., 113(S), 1-130. | eng |
| dcterms.references | Korevaar, J., Manen, J. V., Dekker, F., Waart, D. D., Boeschoten, E., Krediet, R. & group, N. S. (2004). Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol., 15(11), 2916-2922. | eng |
| dcterms.references | Levey, A., Atkins, R., Coresh, J., Cohen, E., Collins, A., Eckardt, K.-U., . . . Eknoyan, G. (2007). Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney International, 1-13. | eng |
| dcterms.references | Lewis, E., Hunsicker, L., Bain, R. & Rohde, R. (1993). The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. N Engl J Med, 329(20), 1456-1462. | eng |
| dcterms.references | Lewis, E., Hunsicker, L., Clarke, W., Berl, T., Pohl, M., Lewis, J., . . . Group., C. S. (2001). Renoprotective Effect of the Angiotensin- Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Engl J Med., 345(12), 851-860. | eng |
| dcterms.references | Lindberg, J., Husserl, F., Ross, J., . . . et al. (2005). Impact of multidisciplinary, early renal education on vascular access placement. Nephrology News & Issues, 19(3), 35-36. | eng |
| dcterms.references | Locatelli, F., Aljama, P., Bárány, P., Canaud, B., Carrera, F., Eckardt, K., . . . Group. (2004). Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation, 19(Suppl 2), II1-47. | eng |
| dcterms.references | Locatelli, F., Fouque, D., Heimburger, O., Drüeke, T., Cannata- Andía, J., Hörl, W., & Ritz, E. (2002). Nutritional status in dialysis patients: a European consensus. Nephrol Dial Trasplant., 17(4), 563-572. | eng |
| dcterms.references | Locatelli, F., Pisoni, R., Combe, C., . . . et al. (2004). Anemia in hemodialysis patients of five european countries: association with morbidity and mortality in DOPPS. Nephrol. Dial. Transplant, 19, 121-132. | eng |
| dcterms.references | Manen, K. V., Dekker, F., Waart, D. D., Boeschoten, E. & Krediet, R. (2004). Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol, 15, 2916-2922. | eng |
| dcterms.references | Manzor, D. (2017). Historia de la Nefrología. Buenos Aires: Galáctica Ediciones. | spa |
| dcterms.references | Matsushita, K., Velde, M. V., Astor, B., Woodward, M., Levey, A., Jong, P. E., . . . Gansevoort, R. (2010). Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet , 375(9731), 2073-2081. | eng |
| dcterms.references | McMahon, L. P. & MacGinley, R. (2012). KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology, 17(1), 17-19. | eng |
| dcterms.references | Mohanram, A., Zhang, Z., Shahinfar, S., Keane, W., Brenner, B. & Toto, R: (2004). Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int., 66(3), 1131-1138. | eng |
| dcterms.references | Morillas, C., Solá, E. & Coronel, F. (2008). Manejo de la hiperglicemia en enfermedad renal crónica. NefroPlus, 1, 16-22. | spa |
| dcterms.references | Muñoz, P., Rodríguez, C. & Bouza, E. (2005). Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis., 40(4), 581-587. | eng |
| dcterms.references | Navaneethan, S., Nigwekar, S., Sehgal, A. & Strippoli, G. (2009). Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Clin J Am Soc Nephrol., 4(3), 542-551. | eng |
| dcterms.references | Nickolas, T., Frisch, G., Opotowsky, A., Arons, R., & Radhakrishnan, J. (2005). Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2005; 44, 185-197. | eng |
| dcterms.references | NKF (2003). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis., 42(4 Suppl. 3), S1-201. | eng |
| dcterms.references | NKF-K/DOQI (2007). NKF-K/DOQI Clinical Practice Guidelines and Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis., 50(3), 471-530. | eng |
| dcterms.references | NKF-K/DOQI (2006). NKF-DOQI Clinical Practice Guidelines for anemia of Chronic Renal Failure. Am J Kidney Dis., 47(Suppl), S11-145. | eng |
| dcterms.references | NKF-K/DOQI (2007). Clinical Practice Guidelines and Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis., 50, 474. | eng |
| dcterms.references | Obialo, I. C., Okonofua, E. C., Nzerue, M. C., Tayade, A. S. & Riley, L. (1999). Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney International, 56(3), 1058-1063. | eng |
| dcterms.references | ONU (17 de julio de 2000). Resolución 1308. Recuperado el 5 de abril de 2018, de http://www.un.org/es/comun/docs/?symbol=S/ RES/1308%20(2000) | spa |
| dcterms.references | ONU (27 de junio de 2001). Declaración de compromiso en la lucha contra el VIH/SIDA. Recuperado el 7 de abril de 2018, de http:// www.un.org/es/aids/aress262.shtml | spa |
| dcterms.references | ONU (24 de diciembre de 2010). Alcance, modalidades, formato y organización de la Reunión de Alto Nivel de la Asamblea General sobre la Prevención y el Control de las Enfermedades No Transmisibles. Recuperado el 12 de abril de 2018, de http://www.un.org/ es/comun/docs/?symbol=A/RES/65/238 | spa |
| dcterms.references | ONU (16 de septiembre de 2011). Declaración Política de la Reunión de Alto Nivel de la Asamblea General sobre la Prevención y el Control de las Enfermedades No Transmisibles. Recuperado el 12 de mayo de 2018, de http://www.un.org/es/comun/docs/?symbol= A/66/L.1 | spa |
| dcterms.references | OPS/OMS (2011). Prioridades para la salud cardiovascular en las Américas. Mensajes claves para los decisores. Washington DC: OPS/OMS. | spa |
| dcterms.references | OPS/OMS. (18 de septiembre de 2012). Estrategia para la prevención y el control de las Enfermedades No Transmisibles, 2012-2025. Washington DC, USA: Organización Panamericana de la Salud. | spa |
| dcterms.references | OPS/OMS (2014). Plan de acción para la prevención y el control de las enfermedades no transmisibles en las Américas 2013-2019. Washington DC: OPS/OMS. | spa |
| dcterms.references | OPS/OMS (10 de marzo de 2015). La OPS/OMS y la Sociedad Latinoamericana de Nefrología llaman a prevenir la enfermedad renal y a mejorar el acceso al tratamiento. Recuperado el 14 de mayo de 2018, de https://www.paho.org/hq/index.php?option=com_content& view=article&id=10542%3A2015-opsoms-sociedad-latinoamericana-nefrologia-enfermedad-renal-mejorar-tratamiento& catid=740%3Apress-releases&Itemid=1926&lang=es | spa |
| dcterms.references | OPS/OMS (2017a). Epidemia de enfermedad renal crónica en comunidades agrícolas de Centroamérica. Definición de casos, base metodológica y enfoques para la vigilancia de salud pública. Wendy Hoy & Pedro Ordunez. | spa |
| dcterms.references | OPS/OMS (2017b). Fondo Estratégico. Acceso a medicamentos e insumos de salud de calidad en las Américas. Recuperado el 21 de mayo de 2018, de https://www.paho.org/hq/index.php?option= com_content&view=article&id=12163%3Apaho-strategic- fund&catid=8775%3Aabout&Itemid=42005&lang=es | spa |
| dcterms.references | Ordunez, P., Nieto, F. J., Martinez-Piedra, R., Soliz, P., Giraldo, G., Mott, S. & Hoy, W. (2018). Chronic kidney disease mortality trends in selected Central America countries, 1997-2013: clues to an epidemic of chronic interstitial nephritis of agricultural communities. Journal of Epidemiology & Community Health, 72(4). | eng |
| dcterms.references | PAHO/WHO (2011). Non-communicable Diseases in the Americas: Basic Indicators 2011. Washington DC: OPS. | eng |
| dcterms.references | Palmer, S., Navaneethan, S., Craig, J., . . . et al. (2010). Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine, 153, 23-33. | eng |
| dcterms.references | Parving, H., Lehnert, H., Brachner-Mortensen, J., Gomis, R., Andersen, S. & Arner, P. (2001). The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. N Engl J Med., 345(12), 870-878. | eng |
| dcterms.references | Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M. . . . et al. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med., 358(24), 2560-2572. | eng |
| dcterms.references | Physicians, R. C. (2008). National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians. | eng |
| dcterms.references | PNUD (2016). Informe sobre Desarrollo Humano 2016. New York: Lowe-Martin Group. | eng |
| dcterms.references | Raphael, K., Wei, G., Baird, B., Greene, T. & Beddhu, S. (2011). Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int., 79(3), 356-362. | eng |
| dcterms.references | Ravid, M., Lang, R., Rachmani, R. & Lishner, M. (1996). Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med., 156(3), 286-289. | eng |
| dcterms.references | Registro Latinoamericano de Diálisis y Trasplante Renal (2014). | spa |
| dcterms.references | Ruggenenti, P., Perna, A., Gherardi, G., Gaspari, F., Benini, R., & Remuzzi, G. (1998). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet, 352(9136), 1252-1256. | eng |
| dcterms.references | Ruggenenti, P., Perna, A. & Remuzzi, G. (2001). ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the Rein trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol., 12(12), 2832-2837. | eng |
| dcterms.references | Saenz, A., Fernandez-Esteban, I., Mataix, A. . . . et al. (2005). Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 3(CD002966). | eng |
| dcterms.references | Schoolwerth, A., Engelgau, M., Hostetter, T., Rufo, K., Chianchiano, D., McClellan, W., . . . Vinicor, F. (2006). Enfermedad renal crónica: una carencia de la salud pública que requiere un plan de acción. Prev Chronic Dis, 3(2). | spa |
| dcterms.references | Shepherd, J., Kastelein, J., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., . . . et al. (2008). Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol., 1448-1454. | eng |
| dcterms.references | Simon, T. A., Paul, S., Wartenberg, D. & Tokars, J. I. (1999). Tuberculosis in hemodialysis patients in New Jersey: a statewide study. Infect Control Hosp Epidemiol., 20(9), 607-609. | eng |
| dcterms.references | Strippoli, G., Bonifati, C., Craig, M., . . . et al. (2006). Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews, 4(CD006257). | eng |
| dcterms.references | Svensson, M., Schmidt, E., Jorgensen, K. & Christensen, J. (2006). N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placaebo-controlled intervention trial. Clin J Am Soc Nephrol., 1(4), 780-786. | eng |
| dcterms.references | Tanus, R., Sarasino, L., Carlogmano, C., Rodano, J., Diez, O., Triay, C., . . . Tanus, E. (1987). Osteopatía en hemodiálisis crónica: uso de desferroxiamina. Rev Nefrol. Dial. y Trasp., (17), 23-32. | spa |
| dcterms.references | Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. & Thadhani, R. (2003). Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. New England Journal of Medicine, 349(5), 446-456. | eng |
| dcterms.references | The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet, 349(9069), 1857-1863. | eng |
| dcterms.references | Tonelli, M., Isles, C., Curhan, G., Tonkin, A., Pfeffer, M., Shepherd, J., . . . et al. (2004). Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation, 110(12), 1557-1563. | eng |
| dcterms.references | Turnbull, F., Abraira, C., Anderson, R., Byington, R., Chalmers, J., Duckworth, W., . . . et al. (2009). Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 52(11), 2288-2298. | eng |
| dcterms.references | Uhlig, K., Macleod, A., Craig, J., Lau, J., Levey, A., Levin, A., . . . Eknoyan, G. (December de 2006). Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int., 70(12), 2058-2065. | eng |
| dcterms.references | UK, L. R. (2008). National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London: Royal College of Physicians. | eng |
| dcterms.references | ONU (s.f.). El sistema de las Naciones Unidas. Recuperado el 23 de mayo de 2018, de http://www.un.org/es/aboutun/booklet/ ga.shtml | spa |
| dcterms.references | Vallejos, A. (2017). Primer Foro Global de Políticas sobre el Riñón. Rev Nefrol Dial Traspl., 37(2), 79-80. | spa |
| dcterms.references | Wang, P., Lau, J. & Chalmers, T. (1993). Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet, 341(8856), 1306-1309. | eng |
| dcterms.references | Weir, M.-R. (2011). Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success[quest]. Kidney Int., 80(3), 235-237. | eng |
| dcterms.references | WHO (2014). Global status report on noncommunicable diseases 2014. Ginebra: WHO Library Cataloguing-in-Publication Data. | eng |
| dcterms.references | WHO (2017a). Las 10 principales causas de defunción. Recuperado el 13 de mayo de 2018, de http://www.who.int/es/news-room/ fact-sheets/detail/the-top-10-causes-of-death | spa |
| dcterms.references | WHO (2017b). WHO Model List of Essential Medicines. Recuperado el 21 de mayo de 2018, de http://www.who.int/medicines/publications/ essentialmedicines/20th_EML2017.pdf?ua=1 | spa |
| dcterms.references | WHO (s.f.). WHO Model List of Essential Medicines. Recuperado el 27 de abril de 2018, de http://www.who.int/medicines/publications/ essentialmedicines/en/index.html | spa |
| dcterms.references | Wilmer, W., Hebert, L., Lewis, E., Rohde, R., Whittier, F., Cattran, D., . . . Blumenthal, S. (1999). Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis., 34(2), 308-314. | eng |
| dcterms.references | Zeeuw, D. D., Agarwal, R., Amdahl, M., Audhya, P., Coyne, D., Garimella, T., . . . et al. (2010). Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, 376(9752), 1543-1551. | eng |